Nadroparin calcium
Nadroparin calcium is an oligosaccharide pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | — | I82.40 | — | 1 | 6 | 9 | 6 | 21 |
| Thrombosis | D013927 | — | — | — | 1 | 7 | 7 | 7 | 21 |
| Thromboembolism | D013923 | — | — | — | — | 6 | 4 | 3 | 13 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | 6 | 2 | 3 | 11 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 7 | 2 | 9 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | 1 | 2 | 4 | 3 | 9 |
| Embolism | D004617 | — | — | — | 1 | 2 | 3 | 3 | 8 |
| Fibrosis | D005355 | — | — | — | — | — | 4 | 2 | 6 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | 1 | 1 | 3 | 6 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 2 | — | 2 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | 3 | — | 4 | 7 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | 1 | — | 1 | 2 |
| Postpartum period | D049590 | — | — | — | — | 2 | — | — | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | — | 1 | — | — | 1 |
| Extracorporeal membrane oxygenation | D015199 | — | — | — | — | 1 | — | — | 1 |
| Thrombophilia | D019851 | — | D68.59 | — | — | 1 | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
| Knee injuries | D007718 | — | — | — | — | 1 | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | — | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 1 | — | — | — | 1 |
| Cerebral infarction | D002544 | — | I63 | — | 1 | — | — | — | 1 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 2 | 2 |
| Hemostatic disorders | D020141 | — | — | — | — | — | — | 2 | 2 |
| Connective tissue diseases | D003240 | EFO_1001986 | M35 | — | — | — | — | 1 | 1 |
| Undifferentiated connective tissue diseases | D000074079 | — | — | — | — | — | — | 1 | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 1 | 1 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | — | 1 | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | — | — | — | 1 | 1 |
| Genital diseases | D000091662 | — | — | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nadroparin calcium |
| INN | nadroparin calcium |
| Description | Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.
|
| Classification | Oligosaccharide |
| Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109204 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08813 |
| UNII ID | LIA7Z4002P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,238 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,099 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use